Multidimensional definition of the interferonopathy of Down syndrome and its response to JAK inhibition

Individuals with Down syndrome (DS) display chronic hyperactivation of interferon signaling. However, the clinical impacts of interferon hyperactivity in DS are ill-defined. Here, we describe a multiomics investigation of interferon signaling in hundreds of individuals with DS. Using interferon scores derived from the whole blood transcriptome, we defined the proteomic, immune, metabolic, and clinical features associated with interferon hyperactivity in DS. Interferon hyperactivity associates with a distinct proinflammatory phenotype and dysregulation of major growth signaling and morphogenic pathways. Individuals with the highest interferon activity display the strongest remodeling of the peripheral immune system, including increased cytotoxic T cells, B cell depletion, and monocyte activation. Interferon hyperactivity accompanies key metabolic changes, most prominently dysregulated tryptophan catabolism. High interferon signaling stratifies a subpopulation with elevated rates of congenital heart disease and autoimmunity. Last, a longitudinal case study demonstrated that JAK inhibition normalizes interferon signatures with therapeutic benefit in DS. Together, these results justify the testing of immune-modulatory therapies in DS.

[1]  J. Espinosa,et al.  Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model , 2023, Nature Genetics.

[2]  J. Espinosa,et al.  IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome , 2022, Cell reports.

[3]  C. Stephani,et al.  Janus kinase inhibitors for the treatment of COVID-19. , 2022, The Cochrane database of systematic reviews.

[4]  Faisal A. Almalki,et al.  A Comprehensive Overview of Globally Approved JAK Inhibitors , 2022, Pharmaceutics.

[5]  Randall W. Grout,et al.  Health Supervision for Children and Adolescents With Down Syndrome. , 2022, Pediatrics.

[6]  Ryan M. Baxter,et al.  Specialized interferon action in COVID-19 , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Head,et al.  Type I Interferon Signaling Drives Microglial Dysfunction and Senescence in Human iPSC Models of Down Syndrome and Alzheimer’s Disease , 2021, bioRxiv.

[8]  M. Rafii,et al.  Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder , 2021, Journal of neurodevelopmental disorders.

[9]  Ryan M. Baxter,et al.  The COVIDome Explorer researcher portal , 2021, Cell Reports.

[10]  L. Malle,et al.  Down syndrome and type I interferon: not so simple. , 2021, Current opinion in immunology.

[11]  T. Kang,et al.  The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics , 2021, International journal of molecular sciences.

[12]  J. Espinosa,et al.  JAK inhibition for treatment of psoriatic arthritis in Down syndrome , 2021, Rheumatology.

[13]  M. Mayer,et al.  Medical vulnerability of individuals with Down syndrome to severe COVID-19–data from the Trisomy 21 Research Society and the UK ISARIC4C survey , 2021, EClinicalMedicine.

[14]  D. Lio,et al.  Susceptibility to Heart Defects in Down Syndrome Is Associated with Single Nucleotide Polymorphisms in HAS 21 Interferon Receptor Cluster and VEGFA Genes , 2020, Genes.

[15]  J. Espinosa,et al.  JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome. , 2020, Cell reports.

[16]  B. Chicoine,et al.  Medical Care of Adults With Down Syndrome: A Clinical Guideline. , 2020, JAMA.

[17]  D. Chaussabel,et al.  Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome , 2020, Journal of Clinical Immunology.

[18]  Patrick J. Lao,et al.  Further understanding the connection between Alzheimer's disease and Down syndrome , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[19]  A. Iwasaki,et al.  Contributions of maternal and fetal antiviral immunity in congenital disease , 2020, Science.

[20]  J. Espinosa Down Syndrome and COVID-19: A Perfect Storm? , 2020, Cell Reports Medicine.

[21]  S. Antonarakis,et al.  Down syndrome , 2020, Nature Reviews Disease Primers.

[22]  David S. Wishart,et al.  Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis , 2019, Current protocols in bioinformatics.

[23]  J. Espinosa,et al.  Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity , 2019, Proceedings of the National Academy of Sciences.

[24]  Rani K. Powers,et al.  Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors , 2019, Nature Communications.

[25]  S. Ziegler,et al.  TSLP: from allergy to cancer , 2019, Nature Immunology.

[26]  Jennifer A. McWilliams,et al.  Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome. , 2019, Cell reports.

[27]  C. Dunnick,et al.  Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata , 2019, JAAD case reports.

[28]  J. Pennings,et al.  Apigenin as a Candidate Prenatal Treatment for Trisomy 21: Effects in Human Amniocytes and the Ts1Cje Mouse Model , 2018, bioRxiv.

[29]  M. Gerosa,et al.  The use of biologics and small molecules in pregnant patients with rheumatic diseases , 2018, Expert review of clinical pharmacology.

[30]  A. Iwasaki,et al.  Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development. , 2018, Immunity.

[31]  S. Feldman,et al.  Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis , 2018, Inflammatory bowel diseases.

[32]  J. Pennings,et al.  Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome , 2018, Disease Models & Mechanisms.

[33]  Mark D. Robinson,et al.  Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry , 2018, Cell systems.

[34]  A. D’Alessandro,et al.  Red blood cell metabolism in Down syndrome: hints on metabolic derangements in aging. , 2017, Blood advances.

[35]  J. O’Shea,et al.  JAK inhibition as a therapeutic strategy for immune and inflammatory diseases , 2017, Nature Reviews Drug Discovery.

[36]  Ahwan Pandey,et al.  Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation , 2017, Scientific Reports.

[37]  Xiaoyan Qin,et al.  Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis , 2017, Oncotarget.

[38]  Y. Crow,et al.  Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview , 2016, The Journal of experimental medicine.

[39]  B. Skotko,et al.  Estimation of the number of people with Down syndrome in the United States , 2016, Genetics in Medicine.

[40]  Virginia Pascual,et al.  Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients , 2016, Cell.

[41]  Jørgen H Olsen,et al.  Low risk of solid tumors in persons with Down syndrome , 2016, Genetics in Medicine.

[42]  R. Fischer-Betz,et al.  The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation , 2016, Annals of the rheumatic diseases.

[43]  Piet Demeester,et al.  FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry data , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[44]  Eli R. Zunder,et al.  Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm , 2015, Nature Protocols.

[45]  H. Lähdesmäki,et al.  Systematic annotation of celiac disease loci refines pathological pathways and suggests a genetic explanation for increased interferon-gamma levels. , 2015, Human molecular genetics.

[46]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[47]  P. Adlard,et al.  Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease , 2014, Neurobiology of Aging.

[48]  Sean C. Bendall,et al.  Normalization of mass cytometry data with bead standards , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[49]  D. Munn,et al.  Indoleamine 2,3 dioxygenase and metabolic control of immune responses. , 2013, Trends in immunology.

[50]  Larry Gold,et al.  Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.

[51]  V. Pascual,et al.  The interferon-α signature of systemic lupus erythematosus , 2010, Lupus.

[52]  A. Sher,et al.  IL-10 production by CD4+ effector T cells: a mechanism for self-regulation , 2010, Mucosal Immunology.

[53]  W. Bowers,et al.  Interferon-{gamma} differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. , 2009, The American journal of pathology.

[54]  Robert Gentleman,et al.  flowCore: a Bioconductor package for high throughput flow cytometry , 2009, BMC Bioinformatics.

[55]  N. Nowak,et al.  Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. , 2007, Human molecular genetics.

[56]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Y. Tomer,et al.  Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. , 2004, Autoimmunity reviews.

[58]  M. Hattori,et al.  The DNA sequence of human chromosome 21 , 2000, Nature.

[59]  T. Heffernan,et al.  Partial IFN-alpha/beta and IFN-gamma receptor knockout trisomy 16 mouse fetuses show improved growth and cultured neuron viability. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[60]  L. Maroun Anti-interferon immunoglobulins can improve the trisomy 16 mouse phenotype. , 1995, Teratology.

[61]  L. Maroun Interferon effect on ribosomal ribonucleic acid related to chromosome 21 ploidy. , 1979, The Biochemical journal.

[62]  C. Epstein,et al.  Human Chromosome 21 Dosage: Effect on the Expression of the Interferon Induced Antiviral State , 1974, Science.

[63]  J. Lejeune,et al.  [Human chromosomes in tissue cultures]. , 1959, Comptes rendus hebdomadaires des seances de l'Academie des sciences.

[64]  E BOYLAND,et al.  The metabolism of tryptophan. 2. The metabolism of tryptophan in patients suffering from cancer of the bladder. , 1956, The Biochemical journal.

[65]  A. Rzhetsky,et al.  Prevalence of Common Disease Conditions in a Large Cohort of Individuals With Down Syndrome in the United States. , 2021, Journal of patient-centered research and reviews.

[66]  A. Rosen,et al.  Type I interferons: crucial participants in disease amplification in autoimmunity , 2010, Nature Reviews Rheumatology.

[67]  C. Epstein,et al.  Abnormalities in the interferon response and immune systems in Down syndrome: studies in human trisomy 21 and mouse trisomy 16. , 1987, Progress in clinical and biological research.

[68]  C. Epstein,et al.  Synthesis of interferon-induced polypeptides in normal and chromosome 21-aneuploid human fibroblasts: relationship to relative sensitivities in antiviral assays. , 1980, Journal of interferon research.